A Chinese Girl with Novel PLCE1 Mutations and Proliferation of the Mesangium Responded to Tacrolimus Therapy

Tiantian Lin,Jianguo Li,Fenghua Wang,Li Cao,Jianxin Wu,Juan Tu,L.I.N.A. Ji,Houfa Geng,Chaoying Chen,Dakun Chen

DOI: https://doi.org/10.1111/nep.12178

2014-01-01

Nephrology

Abstract:Nearly all children with nephrotic syndrome (NS) and podocyte gene mutations are resistant to steroid and immunosuppressants, except for two cases with PLCE1 mutations and focal segmental glomerulosclerosis (FSGS)/diffuse mesangial sclerosis (DMS) that responded to calcineurin inhibitor cyclosporine A (CsA) therapy. Cases with PLCE1 mutations and proliferation of the mesangium that showed a full and sustained response to the other calcineurin inhibitor tacrolimus (FK506) have not been reported. Two new compound heterozygous missense mutations (577G>A and 2770G>A) in PLCE1 were found in a 2-year-old girl with mild mesangial proliferation (Fig. 1). The PLCE1 gene encodes phospholipase C epsilon 1 (PLCε1). The compound heterozygous gene mutations 577G>A causes V193I, and 2770G>A causes the G924S change, had altered the function of PLCε1. The girl failed to respond to 4 weeks of prednisone, methylprednisolone pulse therapy and mycophenolate mofetil. However, she entered complete remission after 2 weeks of treatment with tacrolimus. She is free of proteinuria and her renal function is normal after more than 2 years of follow-up. The mechanism of action of calcineurin inhibitor on steroid resistant nephrolotic syndrome (SRNS) remains to be determined. Some studies showed that the beneficial effect of calcineurin inhibitor CsA on proteinuria results from thestabilization of the actin cytoskeleton in podocytes. CsA blocks the calcineurin-mediated dephosphorylation of synaptopodin thereby preserving the phosphorylation-dependent synaptopodin-14-3-3β interaction. Preservation of this interaction, in turn, protects synaptopodin from cathepsin Lmediated degradation. Tacrolimus may have a similar effect to CsA as an anti-proteinuric agent. Though the mechanisms of these cases’ responses to therapy remain unknown, some scholars speculate that there might be a critical time window in disease during which treatment with CsA might overcome a putative developmental defect imposed by PLCE1 loss of function. These cases with PLCE1 mutations who respond to calcineurin inhibitors challenge the traditional view that podocyte disease does not require therapy with immunosuppressants, and imply that calcineurin inhibitors have antiproteinuric effects independent of their immunosuppressive effects. This is the first report of a case with PLCE1 novel mutations from China or East Asia, which enlarges the clinical spectrum of PLCE1 mutations. The full and sustained response to treatment suggests that tacrolimus had effects independent of its immunosuppressive actions.